SCHEMBL4677678

SCHEMBL4677678

CC(=O)c1ccc(Cc2nc(C(=O)C=C(O)c3nc[nH]n3)cs2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.39
MAPT P10636 7/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
ALDH1A1 P00352 3/20 0.39
NPC1 O15118 3/20 0.39
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
GAA P10253 2/20 0.39
ALOX12 P18054 1/20 0.39
POLB P06746 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
KMT2A Q03164 4/20 0.37
RAB9A P51151 4/20 0.37
MEN1 O00255 1/20 0.37
KDM4E B2RXH2 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671891 0.90 LMNA (0.40) LMNAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL4676246 0.89 HDAC1 (0.50) LMNAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL4674590 0.88 MAPT (0.53) LMNAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL4674380 0.88 RAB9A (0.47) LMNAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL4674608 0.88 HDAC1 (0.40) LMNAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL4671664 0.87 HDAC1 (0.40) LMNAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL4679021 0.84 HDAC1 (0.38) LMNAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL4671043 0.83 TSHR (0.39) LMNASMN1; SMN2ALDH1A1KMT2AHTT
SCHEMBL4675403 0.82 KMT2A (0.35) LMNASMN1; SMN2ALDH1A1KMT2AHTT
SCHEMBL4675829 0.81 KMT2A (0.36) LMNASMN1; SMN2ALDH1A1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 LMNA 659/4885MAPT 205/4885SMN1; SMN2 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.